London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
- blonca9
- Nov 18, 2024
- 1 min read
Jorge Santos da Silva explains the properties that he believes give Nanobodies versatility and an edge over traditional antibodies, and highlights the company's programs in dermatology and rheumatology.











.png)




